This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Concerns about how to use established minimal residual disease monitoring in the treatment of
NPM1
‐mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID‐1..., British Journal of Haematology, July 2020, Wiley,
DOI: 10.1111/bjh.16985.
You can read the full text:
The following have contributed to this page
